Developer docs
API playgroundTry for free, no card

Search company profiles

Genprex

Full company profile

uuid0004stv

Namestring
Genprex
Legal namestring
Genprex, Inc.
Websiteurl
genprex.com
Company typeenum
Public
Founded yearint
2009
Descriptiontext

Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage biopharmaceutical company founded in 2009 (as Convergen LifeSciences, rebranded in September 2011) and headquartered in Austin, Texas. The company develops gene therapies for two distinct disease areas: oncology (with a primary focus on non-small cell lung cancer and extensive-stage small cell lung cancer) and diabetes (Type 1 and Type 2). Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid, formerly branded Oncoprex), encapsulates plasmid DNA encoding the TUSC2 tumor suppressor gene in the company's proprietary non-viral Oncoprex lipid nanoparticle delivery system, enabling systemic intravenous administration and repetitive dosing due to its non-immunogenic profile. REQORSA is being evaluated in three Phase 1/2 combination trials — Acclaim-1 (with AstraZeneca's Tagrisso for EGFR-mutant NSCLC), Acclaim-2 (with Merck's Keytruda for NSCLC), and Acclaim-3 (with Genentech's Tecentriq for ES-SCLC) — and has received FDA Fast Track Designations for both lung cancer programs plus Orphan Drug Designation for the SCLC program.

The underlying Oncoprex non-viral nanoparticle platform is the core technical asset, supported by patents granted or allowed in 12+ jurisdictions (US, Japan, Europe, Israel, Mexico, Russia, Chile, China, Singapore, Korea, Australia, Canada) covering REQORSA combinations with PD-1 and PD-L1 antibodies through 2037. A second product candidate, GPX-002 (Pdx1/MafA gene therapy licensed from the University of Pittsburgh), targets Type 1 and Type 2 diabetes via intrapancreatic infusion and is advancing toward an IND submission following an FDA meeting in Q1 2026. Manufacturing is supported by Aldevron (plasmid DNA supply) and a CDMO for GPX-002, with clinical operations conducted through academic medical centers including MD Anderson, University of Michigan, University of Kentucky, and Gabrail Cancer Center.

Genprex is pre-revenue with no commercially approved products and no disclosed recurring revenue. Its business model is future licensing/royalty income from combination development partnerships with large pharmaceutical companies and out-licensing of its patented delivery platform. Operations are funded through equity financings — including a 2018 IPO raising $6.4M and multiple subsequent registered direct offerings, most recently two October 2025 transactions totaling approximately $6.1M in primary proceeds (up to $18.2M with warrants). The company has 11-50 employees, a market capitalization of approximately $6.88M as of June 2026, and is navigating Nasdaq minimum bid price non-compliance following a reverse stock split on October 21, 2025.

Short descriptiontext

Genprex is a clinical-stage, NASDAQ-listed gene therapy company developing REQORSA (TUSC2 lipid nanoparticle therapy) for non-small cell and small cell lung cancer and GPX-002 for diabetes, funded through equity financings with no commercial products or recurring revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAustin, United States
HQ citystring
Austin
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
gene therapy, oncology therapeutics, lung cancer treatment, diabetes gene therapy, lipid nanoparticle delivery
Industry4 codes
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code3 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical-stage gene therapy biopharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Pre-Revenue Clinical Development
TypeLicensing Royalties
Description

Genprex is a clinical-stage gene therapy company with no commercially approved products; no recurring product revenue. Operations funded primarily through equity financings (registered direct offerings, at-the-market offerings, private placements) and capital markets activity.

genprex.com
2Licensing and Partnership Income (Future)
TypeLicensing Royalties
Description

Genprex has licensed technologies and entered into combination development partnerships (e.g., University of Pittsburgh exclusive license for diabetes gene therapy; worldwide license for TUSC2+immunotherapy combinations); future potential licensing/royalty income from commercialized products developed with partners.

genprex.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Pricing details1 tier
1No commercial products available; clinical-stage company with no pricing.
ModelOtherBilling cadencePay-as-you-go
Notes

Pre-revenue clinical-stage company; no commercial products to price.

genprex.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Oncoprex® Delivery System
Description

Proprietary non-viral nanoparticle delivery system used to administer Genprex's cancer-fighting genes.

genprex.com
+2 more records
Core offering1 text field

Genprex is a clinical-stage gene therapy company developing investigational immunogene therapies that use its proprietary Oncoprex non-viral lipid nanoparticle delivery system to encapsulate therapeutic plasmid DNA. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), delivers the TUSC2 tumor suppressor gene and is being evaluated in Phase 1/2 trials for non-small cell lung cancer and small cell lung cancer in combination with approved targeted therapies and immunotherapies. The company is also developing GPX-002, a Pdx1/MafA gene therapy licensed from the University of Pittsburgh for Type 1 and Type 2 diabetes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 79% tumor shrinkage when REQORSA combined with ALK inhibitor alectinib in ALK-EML4 NSCLC mouse models
+5 more records
Product overview1 text field

Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company with a platform-plus-modules architecture anchored by its proprietary non-viral Oncoprex® Delivery System (a lipid nanoparticle platform that encapsulates and intravenously delivers therapeutic genes to tumor cells). On top of this delivery platform, Genprex develops a portfolio of gene therapy product candidates: its lead oncology candidate Reqorsa® Gene Therapy (quaratusugene ozeplasmid, formerly branded Oncoprex) targeting non-small cell and small cell lung cancer — evaluated across the Acclaim-1, Acclaim-2, and Acclaim-3 Phase 1/2 clinical trials in combination with Tagrisso, Keytruda, and Tecentriq respectively — and its diabetes candidate GPX-002 (a Pdx1/MafA gene therapy licensed from the University of Pittsburgh) being advanced under the DIA-001/DIA-002 preclinical programs toward an IND submission. The Oncoprex delivery platform underpins both product lines, enabling systemic, non-immunogenic, repeatable dosing of tumor suppressor and other disease-fighting genes.

Product and service3 records
1Reqorsa Gene Therapy (quaratusugene ozeplasmid)
CategoryInvestigational oncology gene therapy
Description

Genprex's lead oncology drug candidate (formerly branded Oncoprex) is a TUSC2 gene therapy delivered via the Oncoprex non-viral nanoparticle delivery system, intended for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It has received FDA Fast Track Designation for both lung cancer programs and Orphan Drug Designation for the SCLC program, and is being evaluated in combination with AstraZeneca's Tagrisso (osimertinib) in Acclaim-1, Merck's Keytruda in Acclaim-2, and Genentech's Tecentriq (atezolizumab) in Acclaim-3 clinical trials.

2Oncoprex Delivery System
CategoryProprietary non-viral nanoparticle delivery platform
Description

Genprex's proprietary non-viral nanovesicle (lipid nanoparticle) delivery system that encapsulates disease-fighting genes and administers them intravenously for uptake by tumor cells. The nanovesicles are non-immunogenic, allowing repetitive therapeutic dosing, and have been clinically proven to selectively target primary and metastatic tumor cells while delivering therapeutic genes effectively.

3GPX-002
CategoryInvestigational diabetes gene therapy
Description

Genprex's diabetes gene therapy candidate based on a Pdx1/MafA gene construct, developed under an exclusive license from the University of Pittsburgh. It is being developed for both Type 1 and Type 2 diabetes using intrapancreatic infusion delivery (technically translatable to humans via endoscopic retrograde cholangiopancreatography). The therapy has shown preclinical proof-of-concept data in reversing hyperglycemia in mouse models and achieving normal glucose tolerance in non-human primates at four to seven months post-treatment.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Genprex entered into a Sponsored Research Agreement with MD Anderson Cancer Center to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa Gene Therapy for NSCLC and SCLC. Research aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials. The collaboration builds on a relationship that began in 2010 and represents Genprex's continued commitment to precision oncology.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-02-10
Description

University of Kentucky added as a clinical trial site for the Acclaim-3 Phase 2 study evaluating REQORSA in combination with Tecentriq as maintenance treatment for extensive stage small cell lung cancer patients, expanding patient enrollment.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-11-19
Description

Genprex added Gabrail Cancer Center in Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 lung cancer gene therapy studies to expand enrollment and accelerate clinical research.

Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2020-02-11
Description

Genprex signed an exclusive license agreement with the University of Pittsburgh for a potentially curative diabetes gene therapy (GPX-002) that could treat Type 1 and Type 2 diabetes. The therapy was invented by Dr. George Gittes, Professor of Surgery at the Children's Hospital of Pittsburgh. Together the two diabetes types affect approximately 30.3 million people in the U.S.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2018-09-27
Description

Aldevron supplies TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in Genprex's clinical development program evaluating Oncoprex immunogene therapy for NSCLC. The agreement establishes a GMP-validated supply of plasmid DNA vectors. Aldevron is a leading contract manufacturing organization based in Fargo, ND with facilities in Madison, WI, and Freiburg, Germany.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2018-05-08
Description

Genprex selected Accenture to provide clinical data management services to help accelerate the clinical development of Oncoprex immunogene therapy for NSCLC.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2018-04-18
Description

Genprex entered an agreement with The University of Texas at Austin Dell Medical School to establish executive offices at the school's Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

REQORSA is being evaluated in combination with AstraZeneca's Tagrisso (osimertinib) in the Acclaim-1 Phase 1/2 clinical trial for NSCLC patients with EGFR mutations. The combination received FDA Fast Track Designation.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

REQORSA is being evaluated in combination with Genentech's Tecentriq (atezolizumab) as maintenance therapy for extensive stage small cell lung cancer in the Acclaim-3 Phase 1/2 clinical trial. The combination received FDA Fast Track Designation and Orphan Drug Designation.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

REQORSA Immunogene Therapy is being evaluated in combination with Merck's Keytruda in NSCLC patients with stage III or IV disease that progressed after Keytruda treatment. The combination received FDA Fast Track Designation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Genprex has partnered with the University of Michigan Rogel Cancer Center and ALK Positive (a non-profit patient-focused research group) for research on Reqorsa treatment for ALK-EML4 positive non-small cell lung cancer.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage cancer gene therapy company developing oncolytic viral immunotherapies for solid tumors; directly comparable as a small-cap clinical-stage oncology gene therapy peer in lung cancer with similar FDA-designated programs and trial-stage economics.

TypeDirect peer
Description

Clinical-stage gene and cell therapy company with a non-viral UltraCAR-T platform and oncology focus including lung cancer programs; comparable as a gene therapy peer using non-viral delivery for solid tumors and hematologic malignancies.

TypeDirect peer
Description

Clinical-stage immuno-oncology and gene therapy company with non-viral Sleeping Beauty platform for CAR-T and TCR programs; directly comparable as a small clinical-stage gene therapy peer facing similar capital-constrained execution dynamics.

TypeDirect peer
Description

Clinical-stage DNA medicine company developing DNA-based immunotherapies and gene therapies delivered via electroporation; directly comparable as a clinical-stage gene-based oncology peer with similar combination IO strategies.

TypeDirect peer
Description

Clinical-stage immunotherapy company developing neoantigen-based cancer vaccines and gene-therapy-adjacent oncology approaches for lung cancer and other solid tumors; directly comparable as a clinical-stage IO gene therapy peer focused on checkpoint-resistant patients.

6Trizell (Japan Tobacco / Toray)
TypeDirect peer
Description

Clinical-stage gene therapy company developing oncolytic virus and gene therapy for cancer including lung cancer indications; comparable as a clinical-stage oncology gene therapy peer with combination and intratumoral delivery approaches.

TypeEmerging player
Description

Clinical-stage RNA medicines company using lipid nanoparticle delivery for vaccines and rare disease therapeutics; comparable as a lipid nanoparticle delivery peer for nucleic acid payloads, sharing platform-level delivery technology overlap with Genprex's Oncoprex system.

TypeBroad incumbent
Description

Large oncology immunotherapy company with multiple cancer programs including mRNA-based and gene-therapy-adjacent approaches for solid tumors; broadly comparable as an incumbent IO player using nucleic acid platforms for cancer, though with vastly greater scale.

TypeBroad incumbent
Description

Large biopharma with a cell therapy program for Type 1 diabetes and broader gene-therapy-adjacent pipeline; comparable as an incumbent pursuing curative approaches in diabetes, overlapping with Genprex's GPX-002 therapeutic ambition.

TypeBroad incumbent
Description

Large mRNA and nucleic acid therapeutics company with oncology programs including checkpoint combinations and lipid nanoparticle delivery expertise; broadly comparable as an incumbent using LNP delivery for nucleic acid payloads into oncology indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds12 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genprex

Clinical-stage gene therapy biopharmaceuticalsgenprex.com

Genprex is a clinical-stage, NASDAQ-listed gene therapy company developing REQORSA (TUSC2 lipid nanoparticle therapy) for non-small cell and small cell lung cancer and GPX-002 for diabetes, funded through equity financings with no commercial products or recurring revenue.

What Genprex does

Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage biopharmaceutical company founded in 2009 (as Convergen LifeSciences, rebranded in September 2011) and headquartered in Austin, Texas. The company develops gene therapies for two distinct disease areas: oncology (with a primary focus on non-small cell lung cancer and extensive-stage small cell lung cancer) and diabetes (Type 1 and Type 2). Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid, formerly branded Oncoprex), encapsulates plasmid DNA encoding the TUSC2 tumor suppressor gene in the company's proprietary non-viral Oncoprex lipid nanoparticle delivery system, enabling systemic intravenous administration and repetitive dosing due to its non-immunogenic profile. REQORSA is being evaluated in three Phase 1/2 combination trials — Acclaim-1 (with AstraZeneca's Tagrisso for EGFR-mutant NSCLC), Acclaim-2 (with Merck's Keytruda for NSCLC), and Acclaim-3 (with Genentech's Tecentriq for ES-SCLC) — and has received FDA Fast Track Designations for both lung cancer programs plus Orphan Drug Designation for the SCLC program.

The underlying Oncoprex non-viral nanoparticle platform is the core technical asset, supported by patents granted or allowed in 12+ jurisdictions (US, Japan, Europe, Israel, Mexico, Russia, Chile, China, Singapore, Korea, Australia, Canada) covering REQORSA combinations with PD-1 and PD-L1 antibodies through 2037. A second product candidate, GPX-002 (Pdx1/MafA gene therapy licensed from the University of Pittsburgh), targets Type 1 and Type 2 diabetes via intrapancreatic infusion and is advancing toward an IND submission following an FDA meeting in Q1 2026. Manufacturing is supported by Aldevron (plasmid DNA supply) and a CDMO for GPX-002, with clinical operations conducted through academic medical centers including MD Anderson, University of Michigan, University of Kentucky, and Gabrail Cancer Center.

Genprex is pre-revenue with no commercially approved products and no disclosed recurring revenue. Its business model is future licensing/royalty income from combination development partnerships with large pharmaceutical companies and out-licensing of its patented delivery platform. Operations are funded through equity financings — including a 2018 IPO raising $6.4M and multiple subsequent registered direct offerings, most recently two October 2025 transactions totaling approximately $6.1M in primary proceeds (up to $18.2M with warrants). The company has 11-50 employees, a market capitalization of approximately $6.88M as of June 2026, and is navigating Nasdaq minimum bid price non-compliance following a reverse stock split on October 21, 2025.

Genprex firmographics

Firmographics
Name
Genprex
Legal name
Genprex, Inc.
Website
https://genprex.com
Company type
Public
Founded year
2009
Operating status
Operating
Headcount range
11–50 employees
Short description
Genprex is a clinical-stage, NASDAQ-listed gene therapy company developing REQORSA (TUSC2 lipid nanoparticle therapy) for non-small cell and small cell lung cancer and GPX-002 for diabetes, funded through equity financings with no commercial products or recurring revenue.
Ownership category
akta.pro rank

Genprex industry classification

Industry
Product category
Clinical-stage gene therapy biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAF
Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Gene therapy
  • Oncology therapeutics
  • Lung cancer treatment
  • Diabetes gene therapy
  • Lipid nanoparticle delivery

Where Genprex is headquartered

Location

Headquarters

HQ city
Austin
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Genprex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

  1. Pre-Revenue Clinical Development: Genprex is a clinical-stage gene therapy company with no commercially approved products; no recurring product revenue. Operations funded primarily through equity financings (registered direct offerings, at-the-market offerings, private placements) and capital markets activity.
  2. Licensing and Partnership Income (Future): Genprex has licensed technologies and entered into combination development partnerships (e.g., University of Pittsburgh exclusive license for diabetes gene therapy; worldwide license for TUSC2+immunotherapy combinations); future potential licensing/royalty income from commercialized products developed with partners.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goNo commercial products available; clinical-stage company with no pricing.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels8 records

Genprex product offering

Product offering

Core offering

Genprex is a clinical-stage gene therapy company developing investigational immunogene therapies that use its proprietary Oncoprex non-viral lipid nanoparticle delivery system to encapsulate therapeutic plasmid DNA. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), delivers the TUSC2 tumor suppressor gene and is being evaluated in Phase 1/2 trials for non-small cell lung cancer and small cell lung cancer in combination with approved targeted therapies and immunotherapies. The company is also developing GPX-002, a Pdx1/MafA gene therapy licensed from the University of Pittsburgh for Type 1 and Type 2 diabetes.

Product overview

Genprex, Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company with a platform-plus-modules architecture anchored by its proprietary non-viral Oncoprex® Delivery System (a lipid nanoparticle platform that encapsulates and intravenously delivers therapeutic genes to tumor cells). On top of this delivery platform, Genprex develops a portfolio of gene therapy product candidates: its lead oncology candidate Reqorsa® Gene Therapy (quaratusugene ozeplasmid, formerly branded Oncoprex) targeting non-small cell and small cell lung cancer — evaluated across the Acclaim-1, Acclaim-2, and Acclaim-3 Phase 1/2 clinical trials in combination with Tagrisso, Keytruda, and Tecentriq respectively — and its diabetes candidate GPX-002 (a Pdx1/MafA gene therapy licensed from the University of Pittsburgh) being advanced under the DIA-001/DIA-002 preclinical programs toward an IND submission. The Oncoprex delivery platform underpins both product lines, enabling systemic, non-immunogenic, repeatable dosing of tumor suppressor and other disease-fighting genes.

Differentiator

Problem solved

Functional benefit

Brands

  • Oncoprex® Delivery System: Proprietary non-viral nanoparticle delivery system used to administer Genprex's cancer-fighting genes.
  • Reqorsa® Gene Therapy (quaratusugene ozeplasmid)
  • GPX-002

Products and services

  • Reqorsa Gene Therapy (quaratusugene ozeplasmid) Genprex's lead oncology drug candidate (formerly branded Oncoprex) is a TUSC2 gene therapy delivered via the Oncoprex non-viral nanoparticle delivery system, intended for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). It has received FDA Fast Track Designation for both lung cancer programs and Orphan Drug Designation for the SCLC program, and is being evaluated in combination with AstraZeneca's Tagrisso (osimertinib) in Acclaim-1, Merck's Keytruda in Acclaim-2, and Genentech's Tecentriq (atezolizumab) in Acclaim-3 clinical trials.
  • Oncoprex Delivery System Genprex's proprietary non-viral nanovesicle (lipid nanoparticle) delivery system that encapsulates disease-fighting genes and administers them intravenously for uptake by tumor cells. The nanovesicles are non-immunogenic, allowing repetitive therapeutic dosing, and have been clinically proven to selectively target primary and metastatic tumor cells while delivering therapeutic genes effectively.
  • GPX-002 Genprex's diabetes gene therapy candidate based on a Pdx1/MafA gene construct, developed under an exclusive license from the University of Pittsburgh. It is being developed for both Type 1 and Type 2 diabetes using intrapancreatic infusion delivery (technically translatable to humans via endoscopic retrograde cholangiopancreatography). The therapy has shown preclinical proof-of-concept data in reversing hyperglycemia in mouse models and achieving normal glucose tolerance in non-human primates at four to seven months post-treatment.

Quantifiable outcome

  • 79% tumor shrinkage when REQORSA combined with ALK inhibitor alectinib in ALK-EML4 NSCLC mouse models
  • +5 more outcomes

Companies that use Genprex

Customer profile

Segments4 records

Ideal customer profiles4 records

Genprex technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Genprex partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered flagship, minor and core.

  • The University of Texas MD Anderson Cancer CenterflagshipStrategic or Co-development Partner · 21 April 2026Genprex entered into a Sponsored Research Agreement with MD Anderson Cancer Center to study TROP2 and PTEN biomarkers that may predict patient response to Reqorsa Gene Therapy for NSCLC and SCLC. Research aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials. The collaboration builds on a relationship that began in 2010 and represents Genprex's continued commitment to precision oncology.
  • University of KentuckyminorImplementation/ SI/ Consulting Partner · 10 February 2026University of Kentucky added as a clinical trial site for the Acclaim-3 Phase 2 study evaluating REQORSA in combination with Tecentriq as maintenance treatment for extensive stage small cell lung cancer patients, expanding patient enrollment.
  • Gabrail Cancer CenterminorImplementation/ SI/ Consulting Partner · 19 November 2025Genprex added Gabrail Cancer Center in Ohio as a new clinical trial site for its Acclaim-1 and Acclaim-3 lung cancer gene therapy studies to expand enrollment and accelerate clinical research.
  • University of PittsburghflagshipOEM/ Whitelabel/ Licensing Partner · 11 February 2020Genprex signed an exclusive license agreement with the University of Pittsburgh for a potentially curative diabetes gene therapy (GPX-002) that could treat Type 1 and Type 2 diabetes. The therapy was invented by Dr. George Gittes, Professor of Surgery at the Children's Hospital of Pittsburgh. Together the two diabetes types affect approximately 30.3 million people in the U.S.
  • AldevroncoreTechnology or Integration · 27 September 2018Aldevron supplies TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in Genprex's clinical development program evaluating Oncoprex immunogene therapy for NSCLC. The agreement establishes a GMP-validated supply of plasmid DNA vectors. Aldevron is a leading contract manufacturing organization based in Fargo, ND with facilities in Madison, WI, and Freiburg, Germany.
  • AccenturecoreImplementation/ SI/ Consulting Partner · 8 May 2018Genprex selected Accenture to provide clinical data management services to help accelerate the clinical development of Oncoprex immunogene therapy for NSCLC.
  • University of Texas at Austin Dell Medical SchoolminorStrategic or Co-development Partner · 18 April 2018Genprex entered an agreement with The University of Texas at Austin Dell Medical School to establish executive offices at the school's Health Discovery Building, joining the WorkSpaces @ Texas Health CoLab.
  • AstraZeneca (Tagrisso/osimertinib)flagshipStrategic or Co-development PartnerREQORSA is being evaluated in combination with AstraZeneca's Tagrisso (osimertinib) in the Acclaim-1 Phase 1/2 clinical trial for NSCLC patients with EGFR mutations. The combination received FDA Fast Track Designation.
  • Genentech / Roche (Tecentriq/atezolizumab)flagshipStrategic or Co-development PartnerREQORSA is being evaluated in combination with Genentech's Tecentriq (atezolizumab) as maintenance therapy for extensive stage small cell lung cancer in the Acclaim-3 Phase 1/2 clinical trial. The combination received FDA Fast Track Designation and Orphan Drug Designation.
  • Merck (Keytruda/pembrolizumab)flagshipStrategic or Co-development PartnerREQORSA Immunogene Therapy is being evaluated in combination with Merck's Keytruda in NSCLC patients with stage III or IV disease that progressed after Keytruda treatment. The combination received FDA Fast Track Designation.
  • University of Michigan Rogel Cancer Center and ALK PositivecoreStrategic or Co-development PartnerGenprex has partnered with the University of Michigan Rogel Cancer Center and ALK Positive (a non-profit patient-focused research group) for research on Reqorsa treatment for ALK-EML4 positive non-small cell lung cancer.

Scale indicators14 records

Recent moves10 records

Expansion highlights6 records

Genprex competitors and assessment

Company assessment

Direct peers

  • Candel Therapeutics: Clinical-stage cancer gene therapy company developing oncolytic viral immunotherapies for solid tumors; directly comparable as a small-cap clinical-stage oncology gene therapy peer in lung cancer with similar FDA-designated programs and trial-stage economics.
  • Precigen: Clinical-stage gene and cell therapy company with a non-viral UltraCAR-T platform and oncology focus including lung cancer programs; comparable as a gene therapy peer using non-viral delivery for solid tumors and hematologic malignancies.
  • Ziopharm Oncology: Clinical-stage immuno-oncology and gene therapy company with non-viral Sleeping Beauty platform for CAR-T and TCR programs; directly comparable as a small clinical-stage gene therapy peer facing similar capital-constrained execution dynamics.
  • Inovio Pharmaceuticals: Clinical-stage DNA medicine company developing DNA-based immunotherapies and gene therapies delivered via electroporation; directly comparable as a clinical-stage gene-based oncology peer with similar combination IO strategies.
  • Gritstone bio: Clinical-stage immunotherapy company developing neoantigen-based cancer vaccines and gene-therapy-adjacent oncology approaches for lung cancer and other solid tumors; directly comparable as a clinical-stage IO gene therapy peer focused on checkpoint-resistant patients.
  • Trizell (Japan Tobacco / Toray): Clinical-stage gene therapy company developing oncolytic virus and gene therapy for cancer including lung cancer indications; comparable as a clinical-stage oncology gene therapy peer with combination and intratumoral delivery approaches.

Emerging players

  • Arcturus Therapeutics: Clinical-stage RNA medicines company using lipid nanoparticle delivery for vaccines and rare disease therapeutics; comparable as a lipid nanoparticle delivery peer for nucleic acid payloads, sharing platform-level delivery technology overlap with Genprex's Oncoprex system.

Broad incumbents

  • BioNTech: Large oncology immunotherapy company with multiple cancer programs including mRNA-based and gene-therapy-adjacent approaches for solid tumors; broadly comparable as an incumbent IO player using nucleic acid platforms for cancer, though with vastly greater scale.
  • Vertex Pharmaceuticals (VX-880 / cell therapy for diabetes): Large biopharma with a cell therapy program for Type 1 diabetes and broader gene-therapy-adjacent pipeline; comparable as an incumbent pursuing curative approaches in diabetes, overlapping with Genprex's GPX-002 therapeutic ambition.
  • Moderna: Large mRNA and nucleic acid therapeutics company with oncology programs including checkpoint combinations and lipid nanoparticle delivery expertise; broadly comparable as an incumbent using LNP delivery for nucleic acid payloads into oncology indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Genprex social profiles

Digital presence

Genprex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genprex leadership team

Management profile

Number of profiles

Profiles4 records

Genprex subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Genprex funding detail

Funding detail

Funding overview

Funding rounds12 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genprex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genprex

What does Genprex do?

Genprex is a clinical-stage gene therapy company developing investigational immunogene therapies that use its proprietary Oncoprex non-viral lipid nanoparticle delivery system to encapsulate therapeutic plasmid DNA. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), delivers the TUSC2 tumor suppressor gene and is being evaluated in Phase 1/2 trials for non-small cell lung cancer and small cell lung cancer in combination with approved targeted therapies and immunotherapies. The company is also developing GPX-002, a Pdx1/MafA gene therapy licensed from the University of Pittsburgh for Type 1 and Type 2 diabetes.

Is Genprex a public or private company?

Genprex is a public company. It is classified as public and is currently operating.

When was Genprex founded?

Genprex was founded in 2009. It employs 11 to 50 people.

Where is Genprex based?

Genprex is headquartered in Austin, United States, in the North America region.

How does Genprex make money?

Two revenue lines are on record. Pre-Revenue Clinical Development is the primary driver. The others are licensing and Partnership Income (Future).

Who are Genprex's main competitors?

Direct peers on record are Candel Therapeutics, Precigen, Ziopharm Oncology, Inovio Pharmaceuticals, Gritstone bio and Trizell (Japan Tobacco / Toray). Arcturus Therapeutics is listed as an emerging player. Broad incumbents are BioNTech, Vertex Pharmaceuticals (VX-880 / cell therapy for diabetes) and Moderna.

Does Genprex have an API?

No public API is recorded for Genprex.

What industry is Genprex in?

Genprex's product category is Clinical-stage gene therapy biopharmaceuticals. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanGenprex to Present Two Diabetes Gene Therapy PathsGenprex will present its diabetes gene delivery approaches at the virtual Future of Cell and Gene Therapy Symposium on November 17-18, 2026. The company will highlight its dual delivery strategy for diabetes gene therapy at the event.FinancialContent Business PageNew Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, IncGenprex announced new patient data showing its gene therapy REQORSA activates cellular repair pathways, including mitochondrial adaptation and autophagy, in lung cancer trials. The company also advanced a Roche Diagnostics collaboration to validate TROP2 and PTEN biomarkers for patient selection, with validation studies expected to complete by late 2026.PRLogNew Patient Data Show REQORSA® Activating Cellular Repair Pathways as Roche Collaboration Advances Precision Lung Cancer Strategy for Genprex, IncGenprex released new clinical patient analysis showing REQORSA activates cellular repair pathways, including mitochondrial function, autophagy, and protein quality control. The company is advancing a precision lung cancer strategy with a Roche Diagnostics partnership and expanding gene therapy programs.FinancialContent Business PageNew TROP2 Research Breakthrough Strengthens REQORSA® Gene Therapy Story as Roche Collaboration Advances Precision Lung Cancer Treatment: Genprex, IncGenprex announced new research linking TROP2 expression to response to its gene therapy REQORSA in non-small cell lung cancer. The findings are supported by preclinical models and patient biopsies, with Roche Diagnostics collaborating to validate the biomarker assay. The company plans to present the data at the 2026 EORTC-NCI-AACR Symposium in Barcelona.FinancialContent Business PagePromising Gene Therapy Supporting Applications Beyond Oncology; Key Presentation at Upcoming Gerontological Society of America Meeting: Genprex, Inc. (Nasdaq: GNPX)Genprex will present research on TUSC2, the gene in its REQORSA gene therapy, at the Gerontological Society of America 2026 meeting. New preclinical data in mice shows TUSC2 loss disrupts mitochondrial function and protein homeostasis in the hippocampus, with sex-specific effects. The findings suggest TUSC2 may play a foundational role in brain health.Business & FinancialPromising Gene Therapy Supporting Applications Beyond Oncology Key Presentation At Upcoming Gerontological Society Of America Meeting: Genprex, Inc. (Nasdaq: GNPX)Genprex will present research on TUSC2, the gene in its cancer gene therapy REQORSA, at the Gerontological Society of America 2026 meeting. New mouse data shows TUSC2 loss disrupts mitochondrial function and protein homeostasis in the aging hippocampus, with sex-specific effects. The findings may inform future applications beyond oncology.Stock TitanGenprex to present TUSC2 aging research at GSA 2026Genprex will present research from its sponsored Meharry Medical College collaboration at the Gerontological Society of America 2026 Annual Scientific Meeting on November 4, 2026. The research focuses on TUSC2 aging.Labiotech.euThe Metabolic Moment: 3 big bets to watch in metabolic diseaseMetabolic disease affects 1.54 billion people, with GLP-1 sales reaching $79 billion last year. Atrogi's ATR-258 improved muscle power by 13% in an eight-week study, while Genprex's gene therapy GPX-002 reversed hyperglycemia in mice. The series debuts October 16.GenengnewsAndelyn to Support Manufacturing Scaleup for Genprex’s Diabetes Gene TherapyGenprex selected Andelyn Biosciences to support scale-up manufacturing for its diabetes gene therapy program, which delivers Pdx1 and MafA genes to the pancreas via an AAV vector. The collaboration will cover process optimization, scale-up, and cGMP manufacturing for clinical trials, with preclinical data showing restored blood glucose in type 1 diabetes mouse models.PR NewswireAndelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy ProgramAndelyn Biosciences will support Genprex's diabetes gene therapy program, including scale-up manufacturing and cGMP clinical production. The AAV-based candidate delivers Pdx1 and MafA genes to the pancreas for Type 1 and Type 2 diabetes. Preclinical data in mouse and nonhuman primate models show restored glucose levels and reduced insulin requirements.